查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2158725

IL-1受體拮抗劑市場：全球市場預測，2026-2032年

IL-1 Receptor Antagonist Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，IL-1 受體拮抗劑市場將成長至 37.8 億美元，複合年成長率為 9.34%。

主要市場統計數據
基準年 2025 20.2億美元
預計年份：2026年 22.1億美元
預測年份 2032 37.8億美元
複合年成長率 (%) 9.34%

IL-1受體拮抗劑：概述

白細胞介素-1 (IL-1) 受體拮抗劑是一類旨在抑制白細胞介素-1（細胞激素）誘導的訊號傳導的治療藥物。其臨床意義涵蓋自體發炎性疾病、風濕性疾病、皮膚病、代謝性疾病和其他發炎性疾病。 IL-1 受體拮抗劑的研發和應用取決於其緩解疾病作用的證據、治療安全性、給藥要求、醫保報銷以及診斷的明確性。

臨床準確性和可近性的提高正在改變這一領域。

該領域的發展趨勢正朝著更具選擇性的患者識別、早期療育以及將發炎的生物學機制與可衡量的臨床結果聯繫起來的治療策略方向轉變。監管機構、臨床醫生和保險公司越來越重視比較證據、長期安全性、感染風險管理和可操作的治療路徑。生物製藥和標靶抗發炎療法之間的競爭也使得藥物差異化變得更加重要，例如給藥的便利性、給藥途徑、對兒童的適用性以及在合併症患者群體中的療效證據。

人工智慧將促進藥物研發、臨床試驗設計和醫療保健的發展。

人工智慧可以透過識別發炎生物標記、分析基因組和轉錄組數據以及改進患者分層來支持IL-1拮抗劑的研究。在臨床開發中，機器學習工具可以幫助識別合格受試者、檢測安全訊號、最佳化臨床實驗參加者招募並識別不同疾病群體中的反應模式。在醫療保健領域，決策支援系統可以輔助治療方案的選擇和監測，但在演算法輸出影響治療之前，檢驗、資料品質、透明度、隱私和臨床醫生監督仍然至關重要。

區域洞察：醫療資源取得差異和不同的臨床優先事項

在北美，先進的專科醫療和強大的臨床研究能力與嚴格的安全、報銷和治療價值監管相結合。在歐洲，實證處方、醫療技術評估和協調的監管標準備受重視，但醫療服務的可近性可能因國家體係而異。亞太地區的需求多種多樣，既有高度發展的生物製藥生態系統，也有不斷擴展的專科醫療基礎設施。拉丁美洲受到公共採購、醫療費用可負擔性、診斷能力和專科醫生可近性差異的影響。在中東，集中採購系統和進口藥品的可近性推動了三級醫療和精準醫療能力的建設。在非洲，診斷、專科醫生可近性、冷鏈物流和資金籌措方面仍存在許多限制，因此可擴展的醫療服務模式尤其重要。

集團洞察：政策協調和貿易協調至關重要。

東南亞國協需要靈活的打入市場策略，以應對其醫療衛生體系成熟度、監管流程和公共部門採購的顯著差異。金磚國家擁有龐大且多元化的患者群體，同時對國內生產、本地臨床證據以及更廣泛地獲取生技藥品表現出日益濃厚的興趣。歐盟受益於通用的法律規範，但在報銷和服務提供方面仍存在國家差異。七國集團（G7）的醫療衛生體系通常支持先進的研究、藥物安全監測和專業化治療路徑，同時也要求強力的證據。海灣合作理事會（GCC）國家通常擁有集中化的三級醫療衛生網路和集中採購，北約國家可能受益於穩健的研究和供應鏈合作，但公眾獲取途徑仍受國家醫療衛生政策的約束。

國家概況：國家醫療健康體系塑造實施路徑

澳洲和加拿大優先考慮由專家主導的醫療服務取得、公共報銷評估以及符合地域特徵的醫療保健。巴西和墨西哥面臨多重優先事項，包括可負擔性、公共部門採購以及擴大專家主導的診斷​​範圍。中國和印度正在努力平衡不斷成長的生物醫學能力與本地化監管、發展生產能力以及確保不同人群廣泛獲得醫療服務之間的關係。日本和韓國擁有完善的臨床基礎設施和較高的監管要求，重點在於安全性、上市後監測和治療效果。法國、德國、義大利、西班牙和英國擁有強大的專家能力，但在評估、採購和報銷機制方面存在差異。俄羅斯的採納路徑受到國內供應狀況、監管要求和醫療保健系統限制的影響。美國繼續優先考慮由專家主導的處方、實證醫學證據的產生、保險公司的覆蓋範圍以及安全性監測。

領導者行動指南：共同建構證據、獲取途徑和增強韌性

產業領導者應優先考慮能夠清晰界定患者群體、臨床顯著終點以及在現有抗發炎藥物框架內定位的證據。伴隨診斷、真實世界數據和透明的安全監測能夠增強臨床醫生和支付方的信心。准入計畫應從一開始就考慮冷鏈要求、給藥環境、兒童用藥和公共採購。區域商業模式應根據當地法規和報銷條件進行調整，而不是一概複製。各組織也應建立負責任的人工智慧管治，實現關鍵資訊來源多元化，加強藥物安全監測，並與臨床醫師和病患團體合作進行治療教育。

調查方法：基於證據的市場狀況評估

本執行摘要採用結構化的定性評估方法，分析了IL-1受體拮抗劑的研發與應用。分析內容包括：治療的生物學基礎、臨床證據的需求、監管和報銷因素、醫療服務系統現狀、區域和國家體系特徵、供應鏈考量以及人工智慧的潛在作用。所有分析均不涉及任何市場估算、預測、市場佔有率、公司名稱或未經證實的數字聲明。對國家和地區的觀察結果僅作為背景模式進行解讀，而非商業性績效的衡量標準。

結論：成功取決於準確性、概念驗證和可執行性。

IL-1受體拮抗劑在標靶發炎管理中發揮至關重要的作用，但其影響遠不止於藥理層面。嚴格的病患篩選、可靠的比較證據、負責任的安全管理以及切實可行的給藥模式，將決定其在不同醫療保健系統中的臨床價值。那些能夠將科學嚴謹性與公平獲取、穩健營運和規範的數位化創新相結合的領導者，將更有利於推動其永續應用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 IL-1受體拮抗劑市場：依適應症分類

  • 冷吡啉相關週期性綜合症
  • 痛風
  • 類風濕性關節炎

第8章：IL-1受體拮抗劑市場：依給藥途徑分類

  • 腹腔內給藥
  • 靜脈
    • 點滴袋
    • 管瓶
  • 皮下
    • 預填充筆
    • 預填充式注射器
      • 多劑量
      • 單一劑量

第9章：IL-1受體拮抗劑市場：按劑型分類

  • 自動噴油器
  • 液體
  • 粉末
  • 預填充式注射器
    • 多劑量
    • 單一劑量

第10章：IL-1受體拮抗劑市場：依患者類型分類

  • 成人
  • 兒童

第11章 IL-1受體拮抗劑市場：依最終用戶分類

  • 家庭醫療保健
  • 醫院
  • 專科診所

第12章：IL-1受體拮抗劑市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專科藥房

第13章：IL-1受體拮抗劑市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 IL-1受體拮抗劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 IL-1受體拮抗劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Cytos Biotechnology AG
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Janssen Biotech, Inc.
  • Kiniksa Pharmaceuticals, Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Olatec Therapeutics, Inc.
  • Protagonist Therapeutics, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
  • Swedish Orphan Biovitrum AB
  • Vertex Pharmaceuticals Incorporated
  • XBiotech Inc.
  • XOMA Corporation

第18章 主要專家

Product Code: MRR-4654A89DBBB0

The IL-1 Receptor Antagonist Market is projected to grow by USD 3.78 billion at a CAGR of 9.34% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.02 billion
Estimated Year [2026] USD 2.21 billion
Forecast Year [2032] USD 3.78 billion
CAGR (%) 9.34%

IL-1 Receptor Antagonists: Executive Overview

IL-1 receptor antagonists are therapeutic agents designed to inhibit signaling driven by interleukin-1, a cytokine associated with inflammation, immune activation, and tissue damage. Their clinical relevance spans autoinflammatory, rheumatic, dermatologic, metabolic, and other inflammatory conditions. Development and adoption are shaped by evidence of disease-modifying activity, treatment safety, administration requirements, reimbursement, and diagnostic clarity.

Clinical Precision and Access Are Reshaping the Field

The landscape is shifting toward more selective patient identification, earlier intervention, and treatment strategies that connect inflammatory biology with measurable clinical outcomes. Regulators, clinicians, and payers are placing greater emphasis on comparative evidence, long-term safety, infection-risk management, and practical treatment pathways. Competition among biologic and targeted anti-inflammatory approaches also increases the importance of differentiation through dosing convenience, route of administration, pediatric usability, and evidence across comorbid populations.

Artificial Intelligence Strengthens Discovery, Trial Design, and Care

Artificial intelligence can support IL-1 antagonist research by identifying inflammatory biomarkers, analyzing genomic and transcriptomic data, and improving patient stratification. In clinical development, machine-learning tools may help locate eligible participants, detect safety signals, optimize trial recruitment, and identify response patterns across heterogeneous diseases. In care delivery, decision-support systems can assist with treatment selection and monitoring, although validation, data quality, transparency, privacy, and clinician oversight remain essential before algorithmic outputs influence therapy.

Regional Insights: Uneven Access and Differing Clinical Priorities

North America combines advanced specialty care and strong clinical research capacity with close scrutiny of safety, reimbursement, and treatment value. Europe emphasizes evidence-based prescribing, health-technology assessment, and coordinated regulatory standards, while access can vary across national systems. Asia-Pacific presents diverse needs, ranging from highly developed biopharmaceutical ecosystems to expanding specialist infrastructure. Latin America is influenced by public procurement, affordability, diagnostic capacity, and uneven specialist access. The Middle East is strengthening tertiary and precision-care capabilities, with adoption shaped by centralized purchasing and imported-medicine access. Africa continues to face constraints involving diagnosis, specialist availability, cold-chain logistics, and financing, making scalable delivery models particularly important.

Group Insights: Policy Alignment and Trade Connectivity Matter

ASEAN countries are likely to require flexible access strategies that reflect substantial differences in health-system maturity, regulatory processes, and public-sector purchasing. BRICS members combine large and diverse patient populations with growing interest in domestic manufacturing, local clinical evidence, and broader biologic access. The European Union benefits from shared regulatory structures but retains national differences in reimbursement and service delivery. G7 health systems generally support sophisticated research, pharmacovigilance, and specialist treatment pathways, while demanding robust evidence. GCC countries often have concentrated tertiary-care networks and centralized procurement, and NATO members may benefit from resilient research and supply-chain cooperation, although civilian access remains governed by national health policies.

Country Insights: National Systems Shape Adoption Pathways

Australia and Canada emphasize specialist-led access, public reimbursement evaluation, and geographically responsive care. Brazil and Mexico face the combined priorities of affordability, public-sector procurement, and expansion of specialist diagnosis. China and India are balancing growing biomedical capability with regulatory localization, manufacturing development, and broad access across diverse populations. Japan and South Korea have advanced clinical infrastructure and strong regulatory expectations, with attention to safety, post-market monitoring, and treatment practicality. France, Germany, Italy, Spain, and the United Kingdom differ in assessment, procurement, and reimbursement mechanisms despite extensive specialist capacity. Russia's pathway is influenced by domestic supply considerations, regulatory conditions, and healthcare-system constraints. The United States remains highly focused on specialist prescribing, evidence generation, payer coverage, and safety monitoring.

Actions for Leaders: Build Evidence, Access, and Resilience Together

Industry leaders should prioritize well-defined patient populations, clinically meaningful endpoints, and evidence that clarifies positioning against established anti-inflammatory options. Companion diagnostic work, real-world evidence, and transparent safety monitoring can improve confidence among clinicians and payers. Access planning should address cold-chain requirements, administration settings, pediatric use, and public procurement from the outset. Regional operating models should be tailored to local regulatory and reimbursement conditions rather than replicated uniformly. Organizations should also establish responsible AI governance, diversify critical supply inputs, strengthen pharmacovigilance, and collaborate with clinicians and patient groups on treatment education.

Methodology: Evidence-Led Market Landscape Assessment

This executive summary uses a structured qualitative assessment of IL-1 receptor antagonist development and use. The analysis considers therapeutic biology, clinical evidence needs, regulatory and reimbursement factors, healthcare delivery conditions, regional and country-level system characteristics, supply-chain considerations, and the potential role of artificial intelligence. Insights are framed without market estimates, market shares, forecasts, company references, or unsupported numerical claims. Country and group observations are interpreted as contextual patterns rather than measurements of commercial performance.

Conclusion: Success Depends on Precision, Proof, and Practical Delivery

IL-1 receptor antagonists occupy an important position in targeted inflammation management, but their impact depends on more than pharmacology alone. Strong patient selection, credible comparative evidence, responsible safety management, and workable delivery models will determine clinical value across diverse health systems. Leaders that connect scientific precision with equitable access, resilient operations, and disciplined digital innovation will be best positioned to support durable adoption.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. IL-1 Receptor Antagonist Market, by Indication

  • 7.1. Introduction
  • 7.2. Cryopyrin-Associated Periodic Syndromes
  • 7.3. Gout
  • 7.4. Rheumatoid Arthritis

8. IL-1 Receptor Antagonist Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Intraperitoneal
  • 8.3. Intravenous
    • 8.3.1. Infusion Bag
    • 8.3.2. Vial
  • 8.4. Subcutaneous
    • 8.4.1. Pre-Filled Pen
    • 8.4.2. Prefilled Syringe
      • 8.4.2.1. Multi-Dose
      • 8.4.2.2. Single-Dose

9. IL-1 Receptor Antagonist Market, by Dosage Form

  • 9.1. Introduction
  • 9.2. Auto-Injector
  • 9.3. Liquid
  • 9.4. Powder
  • 9.5. Prefilled Syringe
    • 9.5.1. Multi-Dose
    • 9.5.2. Single-Dose

10. IL-1 Receptor Antagonist Market, by Patient Type

  • 10.1. Introduction
  • 10.2. Adult
  • 10.3. Pediatric

11. IL-1 Receptor Antagonist Market, by End-User

  • 11.1. Introduction
  • 11.2. Home Healthcare
  • 11.3. Hospital
  • 11.4. Specialty Clinic

12. IL-1 Receptor Antagonist Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacy
  • 12.3. Online Pharmacy
  • 12.4. Retail Pharmacy
  • 12.5. Specialty Pharmacy

13. IL-1 Receptor Antagonist Market, by Region

  • 13.1. Introduction
  • 13.2. Asia-Pacific
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Europe
  • 13.6. Middle East
  • 13.7. Africa

14. IL-1 Receptor Antagonist Market, by Group

  • 14.1. Introduction
  • 14.2. ASEAN
  • 14.3. GCC
  • 14.4. European Union
  • 14.5. BRICS
  • 14.6. G7
  • 14.7. NATO

15. IL-1 Receptor Antagonist Market, by Country

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. United Kingdom
  • 15.7. Germany
  • 15.8. France
  • 15.9. Russia
  • 15.10. Italy
  • 15.11. Spain
  • 15.12. China
  • 15.13. India
  • 15.14. Japan
  • 15.15. Australia
  • 15.16. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. Market Concentration Analysis, 2025
    • 16.2.1. Concentration Ratio (CR)
    • 16.2.2. Herfindahl Hirschman Index (HHI)
  • 16.3. Recent Developments & Impact Analysis, 2025
  • 16.4. Product Portfolio Analysis, 2025
  • 16.5. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Amgen Inc.
  • 17.3. AstraZeneca PLC
  • 17.4. Bristol-Myers Squibb Company
  • 17.5. Cytos Biotechnology AG
  • 17.6. Eli Lilly and Company
  • 17.7. GlaxoSmithKline plc
  • 17.8. Janssen Biotech, Inc.
  • 17.9. Kiniksa Pharmaceuticals, Ltd.
  • 17.10. Merck & Co., Inc.
  • 17.11. Novartis AG
  • 17.12. Olatec Therapeutics, Inc.
  • 17.13. Protagonist Therapeutics, Inc.
  • 17.14. Regeneron Pharmaceuticals, Inc.
  • 17.15. Roche Holding AG
  • 17.16. Sanofi
  • 17.17. Swedish Orphan Biovitrum AB
  • 17.18. Vertex Pharmaceuticals Incorporated
  • 17.19. XBiotech Inc.
  • 17.20. XOMA Corporation

18. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global IL-1 Receptor Antagonist Market, Years Considered for the Study
  • FIGURE 2. Global IL-1 Receptor Antagonist Market, Research Design
  • FIGURE 3. Global IL-1 Receptor Antagonist Market, Research Framework
  • FIGURE 4. Global IL-1 Receptor Antagonist Market, Data Triangulation
  • FIGURE 5. Global IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global IL-1 Receptor Antagonist Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 7. Global IL-1 Receptor Antagonist Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2025 vs 2032 (%)
  • FIGURE 9. Global IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global IL-1 Receptor Antagonist Market Size, by Dosage Form, 2025 vs 2032 (%)
  • FIGURE 11. Global IL-1 Receptor Antagonist Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global IL-1 Receptor Antagonist Market Size, by Patient Type, 2025 vs 2032 (%)
  • FIGURE 13. Global IL-1 Receptor Antagonist Market Size, by Patient Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global IL-1 Receptor Antagonist Market Size, by End-User, 2025 vs 2032 (%)
  • FIGURE 15. Global IL-1 Receptor Antagonist Market Size, by End-User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 17. Global IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global IL-1 Receptor Antagonist Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 19. Global IL-1 Receptor Antagonist Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global IL-1 Receptor Antagonist Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global IL-1 Receptor Antagonist Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 22. Global IL-1 Receptor Antagonist Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global IL-1 Receptor Antagonist Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global IL-1 Receptor Antagonist Market Segmentation & Coverage
  • TABLE 2. Global IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 4. Global Cryopyrin-Associated Periodic Syndromes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Cryopyrin-Associated Periodic Syndromes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Cryopyrin-Associated Periodic Syndromes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Gout Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Gout Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Gout Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Rheumatoid Arthritis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Rheumatoid Arthritis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Rheumatoid Arthritis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 14. Global Intraperitoneal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 15. Global Intraperitoneal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 16. Global Intraperitoneal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 17. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Infusion Bag Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 21. Global Infusion Bag Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 22. Global Infusion Bag Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 23. Global Vial Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Vial Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Vial Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Pre-Filled Pen Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 30. Global Pre-Filled Pen Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 31. Global Pre-Filled Pen Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 32. Global Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 33. Global Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 34. Global Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 35. Global Multi-Dose Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 36. Global Multi-Dose Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 37. Global Multi-Dose Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 38. Global Single-Dose Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global Single-Dose Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global Single-Dose Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 42. Global Auto-Injector Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 43. Global Auto-Injector Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 44. Global Auto-Injector Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 45. Global Liquid Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Global Liquid Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 47. Global Liquid Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 48. Global Powder Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global Powder Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global Powder Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global Multi-Dose Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 55. Global Multi-Dose Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 56. Global Multi-Dose Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 57. Global Single-Dose Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 58. Global Single-Dose Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 59. Global Single-Dose Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 60. Global IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 61. Global Adult Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Adult Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Adult Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 66. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 67. Global IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 68. Global Home Healthcare Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 69. Global Home Healthcare Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 70. Global Home Healthcare Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 71. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 73. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 74. Global Specialty Clinic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 75. Global Specialty Clinic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 76. Global Specialty Clinic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 77. Global IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 78. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 79. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 80. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 81. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 82. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 83. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 84. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 85. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 86. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 87. Global Specialty Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 88. Global Specialty Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 89. Global Specialty Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 90. Global IL-1 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 91. Asia-Pacific IL-1 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 92. Asia-Pacific IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 93. Asia-Pacific IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 94. Asia-Pacific IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 95. Asia-Pacific IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 96. Asia-Pacific IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 97. Asia-Pacific IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 98. Asia-Pacific IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 99. Asia-Pacific IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 100. Asia-Pacific IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 101. Asia-Pacific IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 102. North America IL-1 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 103. North America IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 104. North America IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 105. North America IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 106. North America IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 107. North America IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 108. North America IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 109. North America IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 110. North America IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 111. North America IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 112. North America IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 113. Latin America IL-1 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 114. Latin America IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 115. Latin America IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 116. Latin America IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 117. Latin America IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 118. Latin America IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 119. Latin America IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 120. Latin America IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 121. Latin America IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 122. Latin America IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 123. Latin America IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 124. Europe IL-1 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 125. Europe IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 126. Europe IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 127. Europe IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 128. Europe IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 129. Europe IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 130. Europe IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 131. Europe IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 132. Europe IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 133. Europe IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 134. Europe IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 135. Middle East IL-1 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 136. Middle East IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 137. Middle East IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 138. Middle East IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 139. Middle East IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 140. Middle East IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 141. Middle East IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 142. Middle East IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 143. Middle East IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 144. Middle East IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 145. Middle East IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 146. Africa IL-1 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 147. Africa IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 148. Africa IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 149. Africa IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 150. Africa IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 151. Africa IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 152. Africa IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 153. Africa IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 154. Africa IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 155. Africa IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 156. Africa IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 157. Global IL-1 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 158. ASEAN IL-1 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 159. ASEAN IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 160. ASEAN IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 161. ASEAN IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 162. ASEAN IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 163. ASEAN IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 164. ASEAN IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 165. ASEAN IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 166. ASEAN IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 167. ASEAN IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 168. ASEAN IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 169. GCC IL-1 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 170. GCC IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 171. GCC IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 172. GCC IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 173. GCC IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 174. GCC IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 175. GCC IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 176. GCC IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 177. GCC IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 178. GCC IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 179. GCC IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 180. European Union IL-1 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 181. European Union IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 182. European Union IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 183. European Union IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 184. European Union IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 185. European Union IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 186. European Union IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 187. European Union IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 188. European Union IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 189. European Union IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 190. European Union IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 191. BRICS IL-1 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 192. BRICS IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 193. BRICS IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 194. BRICS IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 195. BRICS IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 196. BRICS IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 197. BRICS IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 198. BRICS IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 199. BRICS IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 200. BRICS IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 201. BRICS IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 202. G7 IL-1 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 203. G7 IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 204. G7 IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 205. G7 IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 206. G7 IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 207. G7 IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 208. G7 IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 209. G7 IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 210. G7 IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 211. G7 IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 212. G7 IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 213. NATO IL-1 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 214. NATO IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 215. NATO IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 216. NATO IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 217. NATO IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 218. NATO IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 219. NATO IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 220. NATO IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 221. NATO IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 222. NATO IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 223. NATO IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 224. Global IL-1 Receptor Antagonist Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 225. United States IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 226. United States IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 227. United States IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 228. United States IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 229. United States IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 230. United States IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 231. United States IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 232. United States IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 233. United States IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 234. United States IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 235. United States IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 236. Canada IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 237. Canada IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 238. Canada IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 239. Canada IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 240. Canada IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 241. Canada IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 242. Canada IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 243. Canada IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 244. Canada IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 245. Canada IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 246. Canada IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 247. Mexico IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 248. Mexico IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 249. Mexico IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 250. Mexico IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 251. Mexico IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 252. Mexico IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 253. Mexico IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 254. Mexico IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 255. Mexico IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 256. Mexico IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 257. Mexico IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 258. Brazil IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 259. Brazil IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 260. Brazil IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 261. Brazil IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 262. Brazil IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 263. Brazil IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 264. Brazil IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 265. Brazil IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 266. Brazil IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 267. Brazil IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 268. Brazil IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 269. United Kingdom IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 270. United Kingdom IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 271. United Kingdom IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 272. United Kingdom IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 273. United Kingdom IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 274. United Kingdom IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 275. United Kingdom IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 276. United Kingdom IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 277. United Kingdom IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 278. United Kingdom IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 279. United Kingdom IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 280. Germany IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 281. Germany IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 282. Germany IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 283. Germany IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 284. Germany IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 285. Germany IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 286. Germany IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 287. Germany IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 288. Germany IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 289. Germany IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 290. Germany IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 291. France IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 292. France IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 293. France IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 294. France IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 295. France IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 296. France IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 297. France IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 298. France IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 299. France IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 300. France IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 301. France IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 302. Russia IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 303. Russia IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 304. Russia IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 305. Russia IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 306. Russia IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 307. Russia IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 308. Russia IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 309. Russia IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 310. Russia IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 311. Russia IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 312. Russia IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 313. Italy IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 314. Italy IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 315. Italy IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 316. Italy IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 317. Italy IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 318. Italy IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 319. Italy IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 320. Italy IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 321. Italy IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 322. Italy IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 323. Italy IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 324. Spain IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 325. Spain IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 326. Spain IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 327. Spain IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 328. Spain IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 329. Spain IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 330. Spain IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 331. Spain IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 332. Spain IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 333. Spain IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 334. Spain IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 335. China IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 336. China IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 337. China IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 338. China IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
  • TABLE 339. China IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
  • TABLE 340. China IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 341. China IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 342. China IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
  • TABLE 343. China IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 344. China IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 345. China IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 346. India IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 347. India IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 348. India IL-1 Receptor Antagonist Market Size, by